BACKGROUND: Gabapentin, an oral non-opioid analgesic, has been used to decrease pain after a variety of surgical procedures. We hypothesized that premedication with gabapentin would minimize tourniquet-related pain in patients receiving IV regional anesthesia (IVRA). METHODS: Patients undergoing elective hand surgery with IVRA were randomly assigned to one of two study groups using a double-blind study design. The control group (n ϭ 20) received placebo capsules 1 h before the surgery, and the gabapentin group (n ϭ 20) received gabapentin 1.2 g p.o. before the operation. IVRA was achieved in all patients with lidocaine, 3 mg/kg, diluted with saline to a total volume of 40 mL. Fentanyl, 0.5 g/kg IV, was administered as a rescue analgesic during surgery. Sensory and motor block onset and recovery times, tourniquet pain, and quality of anesthesia were assessed at specific time intervals during the perioperative period. Visual analog scale pain scores (0 -10) were recorded during the 24 h follow-up period, and patients received diclofenac, 75 mg IM, if their pain score was Ͼ4. RESULTS: The onset of the sensory and motor block did not differ between the two study groups. However, tourniquet pain scores at 30, 40, 50, and 60 min after cuff inflation were lower in the gabapentin group (P Ͻ 0.05). The time to intraoperative analgesic rescue was prolonged in the gabapentin group (35 Ϯ 10 min vs 21 Ϯ 13 min, P Ͻ 0.05), and less supplemental fentanyl was required (35 Ϯ 47 g vs 83 Ϯ 73 g, P Ͻ 0.05). The quality of anesthesia, as independently assessed by the anesthesiologist and the surgeon, was significantly better in the gabapentin (versus control) group. In the gabapentin group, the time to requesting a rescue analgesic after surgery was prolonged (135 Ϯ 25 min vs 85 Ϯ 19 min, P Ͻ 0.05), and postoperative pain scores at 60 min (3.8 Ϯ 0.9 vs 2.2 Ϯ 0.5) and 120 min (3.2 Ϯ 1.4 vs 1.8 Ϯ 0.8), as well as diclofenac consumption (30 Ϯ 38 mg vs 60 Ϯ 63 mg), were reduced after surgery. CONCLUSIONS: Premedication with oral gabapentin (1.2 g) decreased tourniquetrelated pain and improved the quality of anesthesia during hand surgery under IVRA. Gabapentin also reduced pain scores in the early postoperative period.
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Gabapentin is an anticonvulsant drug that is safe and effective for the treatment of neuropathic pain syndrome (7, 8) , as well as for the prevention of postoperative pain (9 -12) . In animal models of inflammatory pain (13, 14) , gabapentin was shown to reduce hyperalgesia and inhibit C-fiber responses to noxious stimuli (15) by modulating both central and peripheral nociceptive response (16) . Therefore, we tested the hypothesis that premedication with gabapentin would reduce tourniquet pain during IVRA and the need for analgesic medication during hand surgery, while improving the overall quality of the intraoperative conditions. The secondary objectives of this study were to evaluate the onset and recovery of the sensory and motor blockade, as well as the severity of postoperative pain.
METHODS
After obtaining approval of the Institutional Ethics Committee at Trakya University, and written informed patient consent, 40 ASA physical status I-II patients scheduled for elective hand surgery were enrolled in this double-blind study from October 2004 through December 2005. Patients with Raynaud's syndrome, sickle cell anemia, chronic pain syndromes, use of opioid analgesics or gabapentin Յ24 h before surgery, or known allergy to any of the study medications were excluded from participating in this study. The patients were randomized to one of two treatment groups based on a computer-generated randomization sequence. Identical-appearing capsules containing either gabapentin 400 mg or an inert substance (placebo) were prepared by the pharmacy department to insure blinding of the patients and the investigators. The selected dose of gabapentin (1.2 g) was based on earlier premedication studies (10, 12) .
Patients randomized to the control group (n ϭ 20) received three placebo capsules 1 h before surgery, and the gabapentin group (n ϭ 20) received three gabapentin 400 mg capsules (Neurontin, Pfizer, Goedecke GmbH, Germany) 1 h before surgery with a sip of water. All patients were premedicated with midazolam, 0.4 mg/kg p.o., 45 min before the surgical procedure. Mean arterial blood pressure (MAP), oxygen saturation (Spo 2 ), and heart rate (HR) values were recorded at 5 min intervals in the operating room. Two IV cannulae were placed, one in a vein on the dorsum of the operative hand for the IVRA, and the second in the opposite hand for administering supplemental medications and fluid during the operation.
After a pneumatic double tourniquet had been placed around the upper arm, the extremity was elevated and exsanguinated with an Esmarch bandage. The proximal cuff was then inflated to 250 mm Hg (or 100 mm Hg above the systolic blood pressure), and circulatory isolation of the arm was verified by inspection, absence of radial pulse, and loss of the pulse oximetry tracing in the ipsilateral index finger. The IVRA was performed using lidocaine, 3 mg/kg, diluted with saline to a total volume of 40 mL and injected over 90 s.
Sensory block was assessed every 30 s after injection of the lidocaine using a standardized pinprick technique with a 22-gauge short-beveled needle. The patient's response was evaluated in the dermatomal sensory distribution of the medial and lateral antebrachial cutaneous, ulnar, median, and radial nerves.
Motor function was assessed by asking the subject to flex and extend their wrist and fingers at 30 s intervals, and complete motor block was recorded when no voluntary movement was present. The onset time for sensory blockade was the time elapsed from injection of the lidocaine until a complete sensory block was achieved in all dermatomes, and the onset time for motor blockade was the time elapsed from injection of lidocaine to achieving a complete motor block.
When an adequate surgical block was achieved, the operative tourniquet (i.e., distal cuff) was inflated to 250 mm Hg and then the proximal cuff was released. The MAP, HR, and Spo 2 values were recorded before and after tourniquet application, at 5, 10, 20, 30, 40, 50, and 60 min after tourniquet inflation, and after release of the tourniquet. Assessments of tourniquet-related pain were performed using an 11-point visual analog scale (VAS), with anchors of 0 ϭ no pain and 10 ϭ worst pain imaginable. These evaluations were performed before and after tourniquet application at 5, 10, 15, 20, 30, 40, and 50 min after the lidocaine injection. When the tourniquet pain score was reported to be Ͼ4, the patient was administered fentanyl, 0.5 g/kg IV boluses, and the total intraoperative fentanyl dose was recorded.
At the end of the operation, the anesthesiologist was asked to quantify the operative conditions according to the following descriptive scale: 4 ϭ excellent (no complaint of pain from patient), 3 ϭ good (patient complained of pain, but supplemental analgesics were not required), 2 ϭ acceptable (patient required supplemental IV analgesia), and 1 ϭ unacceptable (patient required supplemental anesthesia and analgesia). Independently, the operating surgeon was also asked to clinically assess the adequacy of the intraoperative conditions according to the following numeric scale: 4 ϭ excellent, 3 ϭ good, 2 ϭ acceptable, and 1 ϭ poor.
The distal tourniquet was not deflated until a minimum of 30 min after the lidocaine injection. At the end of surgery, tourniquet deflation was performed using a cyclic deflation technique over 1-2 min. Sensory recovery time was noted as the time elapsed after tourniquet deflation until recovery of sensation in all dermatomes as determined using the pinprick technique at 30 s intervals. Motor block recovery time was noted as the time elapsed after tourniquet deflation until return of movement in the fingers. The time until the first analgesic requirement was noted as the time elapsed after tourniquet release until the patient's initial request for pain-relieving medication.
Postoperative assessments of surgical-related pain were made using the same VAS pain scoring system at 1, 2, 4, 6, 12, and 24 h after surgery. Patients were administered diclofenac, 75 mg i.m., at 8 h intervals if the VAS pain score was Ͼ4, and the total diclofenac dosage was recorded. All the evaluations were performed by a blinded observer. The occurrence of nausea, vomiting, skin rash, tachycardia (HR Ͼ100 bpm), bradycardia (HR Ͻ50 bpm), hypotension (MAP Ͻ60 mm Hg), excessive sleepiness, hypertension (MAP Ͼ120 mm Hg), headache, dizziness, tinnitus, and hypoxemia (Spo 2 Ͻ90%), as well as any surgical complications (e.g., wound hematoma), were noted upon discharge from the recovery room and at the end of the 24 h postoperative observation period on the postsurgical ward.
For purposes of the a priori power calculation, a 25% reduction in the tourniquet VAS pain score in the gabapentin (versus control) group was considered to be significant. Based on this pain reduction estimate (and an average standard deviation of 1.375), we calculated that a sample size of 20 patients would provide a Type I error of ␣ ϭ 0.05 and power of 80% (17) . Independent samples Student's t-tests were used for evaluation of the demographic data, intraoperative and postoperative hemodynamic data, the time for the onset and recovery of sensory and motor block, the duration of the operation and tourniquet inflation, analgesic rescue times, and intraoperative and postoperative analgesic requirements. The Mann-Whitney U-test was used for intraoperative and postoperative VAS pain and sedation scores, as well as the quality of anesthesia. The changes in VAS pain and sedation scores over time after study drug administration were assessed using independent samples test with a Bonferroni correction. Summary data are presented as mean (Ϯsd) and median (interquartile ranges) values. Statistical significance was reported when the P value was Ͻ0.05.
RESULTS
A total of 44 patients were assessed for study eligibility. One patient failed to meet the inclusion criteria due to current use of gabapentin, and three patients refused to sign the consent form. All 40 remaining patients were able to complete the study, and no data were excluded from the analysis due to protocol violations. There were also no significant differences in the demographic characteristics, types of hand surgery (e.g., carpal tunnel release and tendon repair), surgery times, or amount of local anesthetic administered between the two study groups (Table 1) . There were also no statistical differences between the two groups with respect to MAP, HR, or Spo 2 values at any of the assessment intervals (data not reported). Sensory and motor block onset and recovery times did not differ between the two study groups (Table 1) . However, VAS scores for tourniquet pain were significantly reduced in the gabapentin group at 30, 40, 50, and 60 min after tourniquet inflation (Fig. 1) . The time to intraoperative fentanyl rescue was prolonged in the gabapentin group (35 Ϯ 10 min vs 21 Ϯ 13 min, P Ͻ 0.05), and the supplemental fentanyl requirement during surgery was also significantly reduced in the gabapentin group (Table 1 ).
The quality of anesthesia scores [medians (and interquartile ranges)] reported by the anesthesiologist (4 [3] [4] vs 2 [1] [2] ) and the surgeon (3 vs 2 ([2-3]), were significantly higher in the gabapentin (versus control) group (P Ͻ 0.05). The time to first postoperative analgesic request was prolonged in the gabapentin group when compared with the control group (135 Ϯ 25 min vs 85 Ϯ 19 min, P Ͻ 0.05). Postoperative VAS pain scores were significantly lower at both 1 and 2 h after surgery in the gabapentin group (Fig. 1) , and the postoperative diclofenac consumption was significantly decreased (30 Ϯ 38 mg vs 60 Ϯ 63 mg, P Ͻ 0.05). 
a Values are mean Ϯ SD and number of patients (n).
There were no statistically significant differences between groups with respect to adverse effects reported during the 24-h postoperative observation period. Two patients in the gabapentin group and three patients in the control group had nausea that required antiemetic treatment, and two patients in the gabapentin group complained of dizziness. Another postoperative complaint was dry mouth in four patients in the gabapentin group and two patients in the control group. None of the patients in either group reported being excessively drowsy (or sleepy) after surgery.
DISCUSSION
The efficacy of gabapentin premedication on intra and postoperative pain scores is controversial (18) . Analogous to our earlier findings in patients undergoing general anesthesia (9, 11) , monitored anesthesia care (10) and central neuroaxis blockade (12) , these findings suggest that patients receiving IVRA can benefit from premedication with oral gabapentin (1.2 g). The results of this study revealed that a single oral dose of gabapentin given as preoperative medication decreased tourniquet-related pain during IVRA by up to 50%, supplemental intraoperative opioid usage by 42%, and postoperative analgesic consumption by 50%, without producing clinically significant side effects. Importantly, both the anesthesiologists and the surgeons rated the quality of anesthesia as better in the gabapentin group. The cost of gabapentin 1.2 g (US $5.04) was comparable to celecoxib 400 mg (US $5.22) and significantly less than dexmedetomidine 0.2 mg (US $54) and clonidine 100 g (US $80). However, all of these non-opioid analgesic adjuvants are more costly than generic opioid analgesics. Therefore, careful cost-benefit analyses are necessary to document the effects of these opioid-sparing compounds on patient outcome (19) .
Tourniquet-related pain is an important factor limiting the more widespread use of IVRA techniques during superficial surgical procedures involving the upper and lower extremities. Although, neuropathic pain produced by nerve compression plays an important role in the etiology of this discomfort (4), other factors which may contribute to tourniquet pain include stimulation of the nerve endings in the cutaneous tissue (which can contribute significantly to the superficial component of tourniquet pain) (20) , skeletal muscle ischemia (21) , and local metabolic changes (22) . Although premedication with gabapentin could also theoretically reduce intraoperative incisional pain, patients were specifically questioned about tourniquet-related pain during the operation.
A predominant peripheral action of gabapentin in neuropathic pain has been suggested as a result of the "up-regulation" of ␣ 2 ␦ Ca 2ϩ channel subunits in the dorsal root ganglia after peripheral nerve injury (23) . In addition, gabapentin has the ability to reduce the increased action potentials observed in dorsal root ganglia neurons. In animal models of inflammatory pain, gabapentin was shown to reduce hyperalgesia (11,24 -26) and inhibit C-fiber responses to noxious stimuli (15) . In addition to its central mode of action, peripheral administration of gabapentin has been shown to reduce local nociception at the site of injury, and this may prove to be beneficial in the treatment of inflammatory pain states (16, 25) . The present study is the first clinical study to assess the usefulness of gabapentin in preventing tourniquet pain during IVRA and in providing residual analgesia in the early postoperative period.
A deficiency of the current study design relates to the seemingly arbitrarily chosen dosage of the study drug (namely, 1.2 g of gabapentin). However, this is the most commonly used dose of gabapentin in both acute and chronic pain studies (7,9 -12) . Although a higher dose of gabapentin might provide greater analgesic efficacy, more side effects (e.g., sedation, dizziness) would also be expected. In order to optimize the premedicant dose of gabapentin, a doseranging study design would be required. In contrast to the usual clinical practice in the United States, the timing of the switch from the proximal to the distal tourniquet cuff was performed upon achieving an adequate surgical sensory and motor blockade (rather than when the patient first complained of tourniquetrelated pain). Another criticism of this preliminary study relates to the fact that the study population involved only patients undergoing minor hand surgery procedures. Further comparative studies are clearly needed in patients undergoing other types of orthopedic surgical procedures. The trend toward a higher incidence of dizziness in studies involving patients receiving gabapentin, 1.2 g, for oral premedication (9 -12) suggests that large scale studies are needed in patients undergoing ambulatory surgery. In conclusion, preoperative administration of a single oral dose of gabapentin (1.2 g) provided a significant clinical benefit by decreasing tourniquetrelated pain and improving intraoperative conditions during IVRA. Pain scores, and the need for analgesic medications during and after these elective hand surgery procedures, were also reduced when gabapentin was used for premedication.
